propafenone has been researched along with Chronic Illness in 27 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the efficacy and safety of propafenone in the prevention of atrial fibrillation (AF) relapse after restoration of sinus rhythm." | 9.11 | Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. ( Altinbas, A; Dogan, A; Ergene, O; Ergene, U; Gedikli, O; Kinay, O; Nazli, C; Ozaydin, M; Ucarci, Y, 2004) |
| "The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study." | 9.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 9.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 9.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 9.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "A placebo-controlled, randomized, double-blind, crossover study was performed in 14 patients with chronic, resistant, ventricular arrhythmias in order to evaluate the efficacy and safety of two new antiarrhythmic agents, propafenone and aprindine." | 9.05 | [Comparison of the anti-arrhythmic effects of propafenone and aprindine in the treatment of refractory chronic ventricular arrhythmias. A randomized double-blind crossover study controlled with placebo]. ( Amici, R; Ciampani, N; Costantini, C; Mocchegiani, R; Pigini, G; Purcaro, A, 1983) |
| "Thirty-two men with chronic ventricular arrhythmias responded to propafenone, a new potent antiarrhythmic agent, in short-term trials with 85% or greater reduction of total ventricular premature complexes (VPCs) per hour, 95% or greater reduction of ventricular couplets (VCs) per hour, and 100% abolition of ventricular tachycardia (VT) beats per 24 hours." | 7.67 | Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience. ( Baker, BJ; de Soyza, N; Dinh, H; Murphy, ML, 1988) |
| "Forty-seven patients with chronic atrial fibrillation and (or) flutter in whom the clinical picture and the length of arrhythmia indicated that drug-mediated cardioversion should be tried were treated with a combination of lidoflazine and propafenon." | 7.66 | [Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)]. ( Beck, OA; Hochrein, H, 1980) |
| "The aim of this study was to investigate the efficacy and safety of propafenone in the prevention of atrial fibrillation (AF) relapse after restoration of sinus rhythm." | 5.11 | Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. ( Altinbas, A; Dogan, A; Ergene, O; Ergene, U; Gedikli, O; Kinay, O; Nazli, C; Ozaydin, M; Ucarci, Y, 2004) |
| "The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study." | 5.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 5.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 5.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 5.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "A placebo-controlled, randomized, double-blind, crossover study was performed in 14 patients with chronic, resistant, ventricular arrhythmias in order to evaluate the efficacy and safety of two new antiarrhythmic agents, propafenone and aprindine." | 5.05 | [Comparison of the anti-arrhythmic effects of propafenone and aprindine in the treatment of refractory chronic ventricular arrhythmias. A randomized double-blind crossover study controlled with placebo]. ( Amici, R; Ciampani, N; Costantini, C; Mocchegiani, R; Pigini, G; Purcaro, A, 1983) |
| "Thirty-two men with chronic ventricular arrhythmias responded to propafenone, a new potent antiarrhythmic agent, in short-term trials with 85% or greater reduction of total ventricular premature complexes (VPCs) per hour, 95% or greater reduction of ventricular couplets (VCs) per hour, and 100% abolition of ventricular tachycardia (VT) beats per 24 hours." | 3.67 | Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience. ( Baker, BJ; de Soyza, N; Dinh, H; Murphy, ML, 1988) |
| "Forty-seven patients with chronic atrial fibrillation and (or) flutter in whom the clinical picture and the length of arrhythmia indicated that drug-mediated cardioversion should be tried were treated with a combination of lidoflazine and propafenon." | 3.66 | [Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)]. ( Beck, OA; Hochrein, H, 1980) |
| "Amiodarone was well tolerated and propafenone produced minor digestive and neurosensory troubles in about half the cases, only in one patient a more pronounced arrhythmogenic effect was observed." | 2.66 | [Comparative study of the efficacy of propafenone and amiodarone in the treatment of chronic ventricular extrasystole]. ( Cosnay, P; Fauchier, JP; Huguet, R; Moquet, B; Rouesnel, P; Wajman, A, 1986) |
| "Diprafenone is a new antiarrhythmic drug with a dominant local anaesthetic action and an additional beta-sympathicolytic activity." | 1.27 | [Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy]. ( Behrenbeck, T; Frenking, B; Gülker, H; Hasfeld, M; Heuer, H, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (48.15) | 18.7374 |
| 1990's | 11 (40.74) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasdemir, C | 1 |
| Musayev, O | 1 |
| Kehribar, DY | 1 |
| Kartal, Y | 1 |
| Can, LH | 1 |
| Dogan, A | 1 |
| Ergene, O | 1 |
| Nazli, C | 1 |
| Kinay, O | 1 |
| Altinbas, A | 1 |
| Ucarci, Y | 1 |
| Ergene, U | 1 |
| Ozaydin, M | 1 |
| Gedikli, O | 1 |
| Narayan, G | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Beck, OA | 1 |
| Hochrein, H | 1 |
| Dimitrov, D | 1 |
| Purcaro, A | 1 |
| Amici, R | 1 |
| Ciampani, N | 1 |
| Costantini, C | 1 |
| Mocchegiani, R | 1 |
| Pigini, G | 1 |
| Naccarella, F | 1 |
| Palmieri, M | 1 |
| del Corso, P | 1 |
| Lombardi, G | 1 |
| Bracchetti, D | 1 |
| Lardoux, H | 1 |
| Valère, PE | 1 |
| Djiane, P | 1 |
| Maarek-Charbit, M | 1 |
| Reimold, SC | 1 |
| Lamas, GA | 1 |
| Cantillon, CO | 1 |
| Antman, EM | 1 |
| Cobbe, SM | 1 |
| Mannino, MM | 1 |
| Mehta, D | 1 |
| Gomes, JA | 1 |
| Bianconi, L | 1 |
| Mennuni, M | 1 |
| Lukic, V | 1 |
| Castro, A | 1 |
| Chieffi, M | 1 |
| Santini, M | 1 |
| Crijns, HJ | 1 |
| Gosselink, AT | 1 |
| Lie, KI | 1 |
| Hsieh, MH | 1 |
| Chen, SA | 1 |
| Wen, ZC | 1 |
| Tai, CT | 1 |
| Chiang, CE | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
| Kochiadakis, GE | 1 |
| Igoumenidis, NE | 1 |
| Parthenakis, FI | 1 |
| Chlouverakis, GI | 1 |
| Vardas, PE | 1 |
| De Simone, A | 1 |
| Stabile, G | 1 |
| Vitale, DF | 1 |
| Turco, P | 1 |
| Di Stasio, M | 1 |
| Petrazzuoli, F | 1 |
| Gasparini, M | 1 |
| De Matteis, C | 1 |
| Rotunno, R | 1 |
| Di Napoli, T | 1 |
| Nielsen, H | 1 |
| Sørum, C | 1 |
| Rasmussen, V | 1 |
| Madsen, JK | 1 |
| Hansen, JF | 1 |
| Kumagai, K | 1 |
| Yamanouchi, Y | 1 |
| Hiroki, T | 1 |
| Arakawa, K | 1 |
| Fauchier, JP | 1 |
| Cosnay, P | 1 |
| Rouesnel, P | 1 |
| Moquet, B | 1 |
| Huguet, R | 1 |
| Wajman, A | 2 |
| Libersa, C | 1 |
| Caron, J | 1 |
| Pladys, A | 1 |
| Beuscart, R | 1 |
| Kacet, S | 1 |
| Connell, C | 1 |
| Dupuis, B | 1 |
| Lekieffre, J | 1 |
| Priori, SG | 1 |
| Bonazzi, O | 1 |
| Facchini, M | 1 |
| Varisco, T | 1 |
| Schwartz, PJ | 1 |
| Jonason, T | 1 |
| Ringqvist, I | 1 |
| Bandh, S | 1 |
| Nilsson, G | 1 |
| Nilsson, H | 1 |
| Lidell, C | 1 |
| Bjerle, P | 1 |
| Olofsson, BO | 1 |
| Dinh, H | 1 |
| Baker, BJ | 1 |
| de Soyza, N | 1 |
| Murphy, ML | 1 |
| Heuer, H | 1 |
| Gülker, H | 1 |
| Hasfeld, M | 1 |
| Frenking, B | 1 |
| Behrenbeck, T | 1 |
| Vázquez García, A | 1 |
| Marcos Sánchez, F | 1 |
| Górgolas Hernández-Mora, P | 1 |
| Durán Pérez-Navarro, A | 1 |
| Vitale, P | 1 |
| De Stefano, R | 1 |
| Perna, B | 1 |
| Romano, A | 1 |
| Iacono, A | 1 |
| Härtel, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
1 review available for propafenone and Chronic Illness
| Article | Year |
|---|---|
Drug therapy of supraventricular tachyarrhythmias--based on efficacy or futility?
Topics: Atrial Fibrillation; Catheter Ablation; Chronic Disease; Humans; Propafenone; Tachycardia, Supravent | 1994 |
16 trials available for propafenone and Chronic Illness
| Article | Year |
|---|---|
Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study.
Topics: Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Chronic Disease; Electric Countersho | 2004 |
[Treatment of chronic ventricular extrasystole with propafenone (Rhythmonorm)].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Chronic Disease; Clin | 1984 |
[Comparison of the anti-arrhythmic effects of propafenone and aprindine in the treatment of refractory chronic ventricular arrhythmias. A randomized double-blind crossover study controlled with placebo].
Topics: Adult; Aged; Aprindine; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Double-Blin | 1983 |
Comparison of the efficacy of propafenone versus disopyramide for complex premature ventricular contractions. Evaluation with long-term monitoring.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Disopyramide | 1982 |
[Treatment of chronic ventricular extrasystole by propafenone (600 mg/d) in 2 or 3 daily doses].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cardiac Complexes, Premature; Chronic Disease; | 1993 |
Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Female; Heart Atria; Heart Disease | 1995 |
Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chron | 1996 |
Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Disopyramide; Do | 1996 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electrocardiography; | 1999 |
Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Combined Modality Therapy; Elect | 1999 |
Propafenone versus quinidine slow-release for the treatment of chronic ventricular arrhythmias.
Topics: Adult; Aged; Cardiac Complexes, Premature; Chronic Disease; Delayed-Action Preparations; Double-Blin | 1990 |
[Comparative study of the efficacy of propafenone and amiodarone in the treatment of chronic ventricular extrasystole].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Cardiac Complexes, Pre | 1986 |
Propafenone versus disopyramide: a double-blind randomized crossover trial in patients presenting chronic ventricular arrhythmias.
Topics: Adult; Aged; Cardiac Complexes, Premature; Chronic Disease; Disopyramide; Double-Blind Method; Femal | 1987 |
Propafenone versus disopyramide for treatment of chronic symptomatic ventricular arrhythmias. A multicenter study.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Disopyramide; Electroc | 1988 |
Efficacy of oral propafenone in chronic ventricular arrhythmias: a placebo controlled cross-over exercise study.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Clinical | 1985 |
10 other studies available for propafenone and Chronic Illness
| Article | Year |
|---|---|
Chronic cough and tachycardia-induced cardiomyopathy in a patient with idiopathic frequent, monomorphic premature ventricular contractions.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chronic Disease; Cough; Female; Humans; Propafenone; | 2013 |
Combined use of 1C and III agents for highly symptomatic, refractory atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Combinations; Female | 2006 |
[Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)].
Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Chronic Disease; Drug Therapy, Co | 1980 |
Current treatment options for paroxysmal supraventricular tachycardia.
Topics: Acute Disease; Catheter Ablation; Chronic Disease; Flecainide; Humans; Propafenone; Tachycardia, Atr | 1994 |
Effects of transcatheter cardioversion on chronic lone atrial fibrillation.
Topics: Atrial Fibrillation; Cardiac Catheterization; Cardiac Pacing, Artificial; Chronic Disease; Disopyram | 1991 |
Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Di | 1987 |
Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience.
Topics: Aged; Arrhythmias, Cardiac; Chronic Disease; Drug Administration Schedule; Electrocardiography; Huma | 1988 |
[Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Female; Humans; Male; Mi | 1987 |
[Oral propafenone in the long-term treatment of chronic ventricular arrhythmia].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Female; Hear | 1986 |
[Low-dose propafenone in chronic ventricular arrhythmia: evaluation by linear regression analysis and correlation with the plasma concentrations of the drug].
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Female; Humans; Kinetics; Male; Middle Aged; Pro | 1986 |